Combination Immunotherapy Targeting Melanoma

The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.

Trial Details

NCT ID

NCT06739226

Phase

PHASE1 / PHASE2

Sponsor

Shenzhen Geno-Immune Medical Institute

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Antigen-specific CAR T, CTL and DCvac to treat melanoma.

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Patients with melanoma have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent …
The expression of melanoma specific antigens is immunohistochemically stained and verified.
Body weight greater than or equal to 40 kg.
Age: ≥18 year and ≤ 75 years of age at the time of enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →